Indication
X-linked hypophosphatemia
11 clinical trials
6 products
1 drug
Product
BurosumabClinical trial
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2017-08-30
Product
burosumabClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2016-12-22
Clinical trial
The Impact of Phosphate Metabolism on Healthy AgingStatus: , Estimated PCD: 2024-08-01
Product
phosphateClinical trial
Calcitriol Monotherapy for X-Linked Hypophosphatemia: Effects on Mineral Ions, Growth and Skeletal ParametersStatus: Recruiting, Estimated PCD: 2025-03-01
Product
CalcitriolClinical trial
Examining the Effect of Burosumab on Muscle Function Using MR SpectroscopyStatus: Completed, Estimated PCD: 2022-08-25
Product
Burosumab InjectionClinical trial
An Investigator-sponsored Phase 3b Open-label Study of Anti- FGF23 Antibody Burosumab (KRN23) in Adult Patients With Xlinked Hypophosphatemia (XLH) in GERmany - BurGERStatus: Completed, Estimated PCD: 2023-03-17
Clinical trial
A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Patients With X-linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2018-10-30
Clinical trial
A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked HypophosphatemiaStatus: Completed, Estimated PCD: 2011-12-01
Drug
VarlilumabProduct
KRN23Clinical trial
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked HypophosphatemiaStatus: Completed, Estimated PCD: 2013-05-01
Clinical trial
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked HypophosphatemiaStatus: Completed, Estimated PCD: 2013-09-01